| Literature DB >> 33763071 |
Claire Germain1,2,3,4,5, Priyanka Devi-Marulkar3,4,5, Samantha Knockaert3,4,5, Jérôme Biton3,4,5, Hélène Kaplon3,4,5, Laïla Letaïef1,2,3,4,5, Jérémy Goc3,4,5, Agathe Seguin-Givelet2,6,7, Dominique Gossot2,6, Nicolas Girard8, Pierre Validire4,9, Marine Lefèvre2,6,9, Diane Damotte3,4,5,10, Marco Alifano3,4,5,11, François M Lemoine1,2, Keith E Steele12, Jean-Luc Teillaud1,2,3,4,5, Scott A Hammond13, Marie-Caroline Dieu-Nosjean1,2,3,4,5.
Abstract
The presence of tertiary lymphoid structures (TLS) in the tumor microenvironment is associated with better clinical outcome in many cancers. In non-small cell lung cancer (NSCLC), we have previously showed that a high density of B cells within TLS (TLS-B cells) is positively correlated with tumor antigen-specific antibody responses and increased intratumor CD4+ T cell clonality. Here, we investigated the relationship between the presence of TLS-B cells and CD4+ T cell profile in NSCLC patients. The expression of immune-related genes and proteins on B cells and CD4+ T cells was analyzed according to their relationship to TLS-B density in a prospective cohort of 56 NSCLC patients. We observed that tumor-infiltrating T cells showed marked differences according to TLS-B cell presence, with higher percentages of naïve, central-memory, and activated CD4+ T cells and lower percentages of both immune checkpoint (ICP)-expressing CD4+ T cells and regulatory T cells (Tregs) in the TLS-Bhigh tumors. A retrospective study of 538 untreated NSCLC patients showed that high TLS-B cell density was even able to counterbalance the deleterious impact of high Treg density on patient survival, and that TLS-Bhigh Treglow patients had the best clinical outcomes. Overall, the correlation between the density of TLS-Bhigh tumors with early differentiated, activated and non-regulatory CD4+ T cell cells suggest that B cells may play a central role in determining protective T cell responses in NSCLC patients.Entities:
Keywords: B cell; immune checkpoint; immune microenvironment; lung cancer; regulatory T cell; tertiary lymphoid structure
Year: 2021 PMID: 33763071 PMCID: PMC7983944 DOI: 10.3389/fimmu.2021.626776
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561